Fennec Pharmaceuticals Reports 73% Revenue Surge on PEDMARK Demand
Event summary
- First-quarter 2026 revenue rose 73% year-over-year to $15.1 million, driven by PEDMARK demand.
- Field sales expansion showing early signs of success with record April 2026 demand.
- Initiated third institution-led clinical study evaluating PEDMARK in new patient populations.
- Four abstracts on PEDMARK accepted for the 2026 ASCO Annual Meeting.
- Cash position increased to $40.1 million as of March 31, 2026.
The big picture
Fennec Pharmaceuticals is capitalizing on growing clinical interest in PEDMARK, expanding its reach beyond pediatric patients to adolescent and young adult populations. The company's strategic investments in field sales and clinical studies are positioning it to capture a larger share of the $500 million U.S. market for cisplatin-based chemotherapy treatments. With a solid financial foundation and upcoming investor conferences, Fennec is poised to build momentum in 2026.
What we're watching
- Commercial Momentum
- Whether the field sales expansion can sustain the current growth trajectory.
- Clinical Validation
- The pace at which additional institution-led studies will validate PEDMARK's broader potential.
- Market Penetration
- How the ASCO presentations will impact physician adoption and patient access.
Related topics